Search Results

Now showing 1 - 5 of 5

Some of the metrics are blocked by your
consent settings
Declaración de la Academia Chilena de Medicina sobre el Título V de la Ley 20.850 (Ley Ricarte Soto) y su proyecto de reglamento De los ensayos clínicos de productos farmacéuticos y elementos de uso médico
(2017)
Gloria López S
;
Gloria Valdés S
;
ROESSLER BONZI, EMILIO JOSE
;
Vicente Valdivieso D
27Scopus© Citations 5
Some of the metrics are blocked by your
consent settings
Bullying and its relationship with the drug use and eating disorders: a comparison between Chilean and Spanish adolescents
(2015)
Carmona-Torres, Jose A.
;
Adolfo J. Cangas
;
Langer, Alvaro I.
;
Aguilar-Parra, Jose M.
;
Gallego, Jose
2
Some of the metrics are blocked by your
consent settings
Declaración de la Academia Chilena de Medicina sobre el Título V de la Ley 20.850 (Ley Ricarte Soto) y su proyecto de reglamento "De los ensayos clínicos de productos farmacéuticos y elementos de uso médico"
(2017)
Gloría López
;
Gloría Valdés
;
ROESSLER BONZI, EMILIO JOSE
;
Vicente Valdivieso
4 1Scopus© Citations 1
Some of the metrics are blocked by your
consent settings
Characteristics of drug interactions in a pediatric intensive care unit [Características de las interacciones farmacológicas en una unidad de cuidados intensivos de pediatría]
(2014)
Claudia Santibáñez S
;
Jorge Roque E
;
Gonzalo Morales V
;
Raúl Corrales W
8Scopus© Citations 14
Some of the metrics are blocked by your
consent settings
Switching Stable Kidney Transplant Recipients to a Generic Tacrolimus Is Feasible and Safe, but It Must Be Monitored
(2017)
Fernando González
;
Elizabeth Arriagada
;
René López
;
René Carrasco
;
NATALIA BERNARDITA GALLARDO CHAPARRO
<jats:p><jats:italic>Background</jats:italic>. Tacrolimus is the primary immunosuppressive drug used in kidney transplant patients. Replacing brand name products with generics is a controversial issue that we studied after a Chilean Ministry of Health mandate to implement such a switch.<jats:italic>Methods</jats:italic>. Forty-one stable Prograf (Astellas) receiving kidney transplant patients were switched to a generic tacrolimus (Sandoz) in a 1 : 1 dose ratio and were followed up for up to 8 months. All other drugs were maintained as per normal practice.<jats:italic>Results</jats:italic>. Neither tacrolimus doses nor their trough blood levels changed significantly after the switch, but serum creatinine did:<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mn fontstyle="italic">1.62</mml:mn><mml:mo>±</mml:mo><mml:mn fontstyle="italic">0.90</mml:mn></mml:math>versus<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M2"><mml:mn fontstyle="italic">1.75</mml:mn><mml:mo>±</mml:mo><mml:mn fontstyle="italic">0.92</mml:mn></mml:math> mg/dL (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M3"><mml:mi>p</mml:mi><mml:mo><</mml:mo><mml:mn fontstyle="italic">0.001</mml:mn></mml:math>). At the same time, five graft biopsies were performed, and two of them showed cellular acute rejection. There were nine infectious episodes treated satisfactorily with proper therapies. No patient or graft was lost during the follow-up time period.<jats:italic>Conclusion</jats:italic>. Switching from brand name tacrolimus to a generic tacrolimus (Sandoz) is feasible and appears to be safe, but it must be monitored carefully by treating physicians.</jats:p>
3

CRIS

Browse

Filters

Settings

Sort By

Results per page

Search Results